Manorama Industries Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/lnptvawy9ra4w1l0lni84v7t.pdf

Key Takeaways


Top-Line Growth & Volume Engine

Ekta Soni: "It's not a thing that there will be there. Of course, the company is very poised and fuelled for the growth, given the capacity we have."

Margin Bridge & Subsidiary Drag

Ekta Soni: "We try to maintain on quarter-to-quarter basis, but whatever guidance we try to give, we will request our shareholders to take on year-on-year basis."

Capacity Expansion & Capex


Burkina Faso & Raw Material Strategy

Ekta Soni: "Given the parlance metrics of the business, if the political uncertainty or insecurity, it does not really affect our operation in Africa. It is a government-backed project for which we have already signed the MoU with government of Burkina Faso."

Balance Sheet & Cash Flow


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth25–30% overall, with 20–30%+ volume growth and ~5% price hikeFY27
Capacity utilization85–90% of 52,000 TPA fractionation capacityFY27
Capex program completionINR 460 crores spent; all projects commissionedBy FY28
Long-term revenueMore than INR 3,500 croresBy FY30
Sustainable margin range45–50% gross margin, 25–27% EBITDA marginOngoing, judged year-on-year
Subsidiary margin normalizationMargins expected to stabilize as operations scaleNo date; transitional costs are first-year
Working capitalMaintain current days and inventory daysOngoing
Plant 1 debottlenecking15,000 MT solvent fractionation plant expansionCurrent fiscal year
Remaining debottlenecking4,500 tons of fractionation capacity to be streamlinedCurrent financial year

Key Metrics

MetricQ4 FY26
Stand-alone revenue₹382.3 cr, FY26 total ₹1,357 cr, up 76.1% YoY
EBITDA₹102.9 cr, margin 26.9%
PAT₹59.5 cr, margin 15.6%
Net foreign exchange loss₹7.58 cr (stand-alone), MTM provision ₹17.05 cr offset by forex income ₹9.47 cr
EBITDA margin (FY26 full year)27.1%, up 230 bps YoY driven by product mix and higher utilization
Volume growth (FY26)80–90% YoY, with 5–10% price growth
CBE revenue contribution~30% of top line, up from 10% two years ago
Value-added product mix (CBE + stearin)70–75% of total sales
Fractionation capacity utilization85% on 40,000 TPA base (excludes debottlenecking)
Stearin volume (FY26)~8,000 metric tons
CBE volume (FY26)~7,500 metric tons
Working capital days125 days (FY26), improved from 151 days in FY25
Net debt-to-equity ratio0.38:1 as of 31 March 2026
ROE40.3% as of 31 March 2026
ROCE33.6% as of 31 March 2026
Operating cash flow (FY26)₹259.4 cr
Capex commitment~₹460 cr over next 2–3 years, ₹52 cr already spent
Raw material sourced from Manorama Africa20–25% in FY26, down from 60% last year
Consolidated EBITDA margin (FY26)~26%, vs 27% standalone, impacted by subsidiary setup costs
Export revenue share57% of total revenue
Forex hedged~60% of net exposure through forward contracts